Services
Company
Legal and Governance
Publication Library / Publications
Cost-effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US
Aim
Evaluate the cost-effectiveness of ocriplasmin in symptomatic vitreomacular adhesion (VMA) with or without full-thickness macular hole ≤400 μm versus standard of care.
Methods
A state-transition model simulated a cohort through disease health states; assignment of utilities to health states reflected the distribution of visual acuity. Efficacy of ocriplasmin was derived from logistic regression models using Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole trial data. Model inputs were extracted from Phase III trials and published literature. The analysis was conducted from a US Medicare perspective.
Results
Lifetime incremental cost-effectiveness ratio was US$4887 per quality-adjusted life year gained in the total population, US$4255 and US$10,167 in VMA subgroups without and with full-thickness macular hole, respectively.
Conclusion
Ocriplasmin was cost effective compared with standard of care in symptomatic VMA.
Authors
A M Khanani, P U Dugel, J A Haller, A L Wagner, B Lescrauwaet, R Schmidt, C Bennison
Journal
Journal of comparative effectiveness research
Therapeutic Area
Ophthalmology
Center of Excellence
Health Economic Modeling & Meta-analysis
Year
2020
Read full article